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GASTRIC CANCER
Two distinct aetiologies of cardia cancer; evidence from
premorbid serological markers of gastric atrophy and
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Background: Non-cardia gastric adenocarcinoma is positively associated with Helicobacter pylori infection
and atrophic gastritis. The role of H pylori infection and atrophic gastritis in cardia cancer is unclear.
Aim: To compare cardia versus non-cardia cancer with respect to the premorbid state of the stomach.
Methods: Nested case–control study. To each of 129 non-cardia and 44 cardia cancers, three controls were
matched. Serum collected a median of 11.9 years before the diagnosis of cancer was tested for anti-H pylori
antibodies, pepsinogen I:II and gastrin.
Results: Non-cardia cancer was positively associated with H pylori (OR 4.75, 95% CI 2.56 to 8.81) and
gastric atrophy (pepsinogen I:II ,2.5; OR 4.47, 95% CI 2.71 to 7.37). The diffuse and intestinal histological
subtypes of non-cardia cancer were of similar proportions and both showed a positive association with
H pylori and atrophy. Cardia cancer was negatively associated with H pylori (OR 0.27, 95% CI 0.12 to
0.59), but H pylori-positive cardia cancer showed an association with gastric atrophy (OR 3.33, 95% CI 1.06
to 10.5). The predominant histological subtype of cardia cancer was intestinal and was not associated with
gastric atrophy compared with the diffuse subtype ((OR 0.72, 95% CI 0.19 to 2.79) vs (OR 3.46, 95% CI 0.32
to 37.5)). Cardia cancer in patients with atrophy had an intestinal: diffuse ratio (1:1) similar to non-cardia
cancer (1.9:1), whereas cardia cancers in patients without atrophy were predominantly intestinal (7:1).
Conclusion: These findings indicate two aetiologies of cardia cancer, one associated with H pylori atrophic
gastritis, resembling non-cardia cancer, and the other associated with non-atrophic gastric mucosa,
resembling oesophageal adenocarcinoma. Serological markers of gastric atrophy may provide the key to
determining gastric versus oesophageal origin of cardia cancer.
S
everal observations indicate that cancers of the cardia
region of the stomach are aetiologically different from
those of the rest of the stomach. Cancers of the mid and
distal stomach (non-cardia cancers) show a strong positive
association with Helicobacter pylori infection, whereas cardia
cancer has negative, positive or no association with H pylori
infection.1 The incidence time trends of cardia and non-cardia
cancer also differ, with the latter falling and the former
remaining static or increasing.2–5
Substantial advances have been made in our understanding
of the aetiology of non-cardia cancer and, in particular, of the
role of H pylori infection. The highest risk of non-cardia cancer
is in patients in whom the infection has induced atrophic
gastritis and low or absent acid secretion.6 Non-cardia cancer is
the result of progression from H pylori superficial gastritis to
atrophic gastritis and hypochlorhydria to dysplasia and finally
to cancer.7
The aetiology of cancer of the gastric cardia region remains
poorly understood. One reason for this may be the anatomical
complexity of the cardia. Cardia mucosa extends from the
oxyntic mucosa of the body of the stomach to the squamous
mucosa of the distal oesophagus. The mucosa consists of
columnar mucosa resembling that of the gastric antrum. In
neonates, the cardia mucosa is only a few millimetres in
length.8 In adults, the cardia mucosa may be larger, and this
expansion may occur by metaplasia of the adjacent mucosa into
cardia-like mucosa.9–12 Proximal extension of cardia mucosa can
occur by metaplastic transformation of the squamous mucosa
of the distal oesophagus—a phenomenon that may be induced
by acidic gastro-oesophageal reflux. Distal extension of cardia
mucosa may arise from atrophic gastritis of oxyntic mucosa
with loss of specialised cells and most commonly induced by H
pylori infection.9 13 When patients present with adenocarcinoma
involving the gastric cardia, it is usually impossible to
determine whether the tumour has arisen from metaplasia of
the distal oesophageal squamous epithelium, from metaplasia
of gastric oxyntic mucosa or from the original cardia mucosa.
In a large nested case–control study in the Norwegian
population, we found that H pylori infection was associated
with an increased risk of non-cardia cancer but with a reduced
risk of cardia cancer.14 The current study was undertaken to
compare cancers at those two sites with respect to premorbid
gastric mucosal atrophy and acid secretion.
The aim of this study was to examine the association
between the state of the gastric mucosa and the risk of
subsequently developing cardia versus non-cardia gastric
cancer.
PATIENTS AND METHODS
This was a nested case–control study. It comprised 101 601 men
and women enrolled in the Norwegian Janus15 cohort as blood
donors in Oslo 1973–86, as participants in the Oslo Study of
Cardiovascular Disease 1972–7316 and as participants in the
Norwegian Counties Study 1974–78 carried out by the National
Health Screening Service in the three counties Oppland, Sogn
og Fjordane and Finnmark.16 17 All solid gastric cancers
diagnosed among the cohort members through 1992 were
Abbreviation: PGI:II, pepsinogen I to pepsinogen II ratio
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identified in The Cancer Registry of Norway. Cases were limited
to individuals with available historical serum from whom
primary tumour tissue could be verified as gastric adenocarci-
noma of unequivocal non-cardia or cardia origin. Of the 230
identified gastric cancer cases, 57 were excluded from the study
because of no remaining or wasted serum (n = 7), no tissue
(n = 2) or only metastatic tumour tissue (n = 10) available for
histological examination, histological type diagnosed or sus-
pected to be other than adenocarcinoma (n = 6), doubt about
the stomach being the primary site of the tumour (n = 2),
gastric resection before the diagnosis of cancer (n = 16), or
disseminated tumour growth precluding determination of
cardia/non-cardia subsite origin (n = 14). To each cancer case,
controls were matched according to gender, date of birth
(within 54 months, 97% within 12 months, median deviation
3 months), date of serum sampling (within 17 months, 99%
within 12 months, median deviation 3 months) and serum
source (blood donors, the Oslo Study of Cardiovascular Disease,
or county within Norwegian Counties Study). In all, three
controls were matched to 162 cases, and two controls were
matched to 11 cases.
The gastric adenocarcinoma cases were classified according
to subsite as tumours of the cardia, fundus, body, antrum or
pylorus in accordance with the International classificaton of diseases
for oncology, second edition19 after review of all clinical, biopsy
and resection reports submitted to the cancer registry. When
needed, endoscopy and radiology reports were consulted.
Cardia cancers were defined as tumours whose centre was
judged to be within 2 cm distal to the gastro-oesophageal
junction. Adenocarcinomas largely or entirely located within
the distal oesophagus were excluded. All diagnoses of
adenocarcinoma were verified on new pathology slides of
biopsy or resection specimens and classified according to
subtype, as given by Laure´n,20 as intestinal, diffuse or other.
The ‘‘other’’ subgroup closely corresponds to ‘‘mixed’’ in newer
terminology.21 Five cases were subtype-unclassifiable because
of insufficient size of the biopsy specimen.
Serum was collected from each cohort member at the start of
follow-up and thereafter kept frozen at 225˚ C. The time lapse
between the last meal and serum sampling was categorised as,1,
1–2, 2–4, 4–8 and .8 h. Serum anti-H pylori IgG concentration
(average of two readings) was measured using the Pyloriset EIA-G
Test Kit (Orion Diagnostica, Espoo, Finland). For detection of
current or previous H pylori infection (ever infection), we chose a
cut-off of 250 U/l, which is lower than the cut-off of 500 U/l
recommended by the manufacturer for detection of current
infection.14 The results of the H pylori serology have been published
previously.14 Serum gastrin concentration was measured using
antibody R98, which detects both gastrin 17 and gastrin 34.22
Serum pepsinogen I and pepsinogen II concentrations were
measured using radioimmunoassay kits (Sorin Biomedica
Diagnostics, Saluggia, Italy).
We validated the ability of serum pepsinogen I to pepsinogen
II ratio (PGI:II) to detect atrophy. This was performed using
stored serum from 175 H pylori-positive patients with non-ulcer
dyspepsia who had undergone endoscopy with antral and body
biopsies. Atrophy of body and antrum was graded as absent,
mild, moderate or severe according to the updated Sydney
classification of gastritis.23 Low PGI:II was valuable in detecting
atrophy involving the gastric body. At a cut-off point of 2.5, the
sensitivity and specificity of PGI:II were 71% and 67%,
respectively, for body atrophy of any severity. The area under
the receiver operating characteristic curve was 0.84 (95% CI
0.69 to 0.99) for body atrophy of any severity. The median
(interquartile range) of PGI:II in patients with none, mild,
moderate and severe atrophy was 5.93 (3.5), 4.73 (3.9), 3.11
(3.5) and 1.85 (0.7), respectively. The non-parametric test
showed that values of PGI:II in patients with moderate
(p,0.05) and severe (p,0.01) atrophy were significantly lower
than those without atrophy.
Statistical analyses
Relative risks of cancer between groups of H pylori serostatus,
PGI:II and gastrin concentrations were estimated as odds ratios
(ORs) with associated 95% CIs using conditional logistic
regression analyses.24 By exploiting the algorithmic equivalence
of proportional hazards regression and conditional logistic
regression, asymptotic ORs were computed using the Cox
module of the SPSS V.7.5 statistical computer software
package, with each matched set as a separate stratum. For
separate analyses of H pylori-seropositive and H pylori-serone-
gative cases and controls, we used unconditional logistic
Table 1 Risk of gastric adenocarcinoma for Helicobacter pylori serostatus, quintiles of serum pepsinogen I:II and quintiles of serum













Negative 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Positive 0.27 (0.12 to 0.59) 4.75 (2.56 to 8.81) 3.96 (1.69 to 9.27) 3.90 (1.11 to 13.7) 5.51 (1.52 to 20.0)
p Value 0.001 ,0.005 0.002 0.034 0.010
Serum pepsinogen I:II
quintiles
5th 6.060–30.973 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
4th 4.803–6.055 0.24 (0.07 to 0.75) 1.21 (0.48 to 3.05) 1.07 (0.30 to 3.74) 0.31 (0.03 to 3.33) 4.35 (0.44 to 43.4)
3rd 3.777–4.795 0.68 (0.27 to 1.74) 2.49 (1.07 to 5.78) 1.50 (0.47 to 4.82) 2.02 (0.46 to 8.86) 13.4 (1.20 to 150)
2nd 2.691–3.774 0.14 (0.03 to 0.71) 5.35 (2.35 to 12.2) 2.96 (0.94 to 9.29) 7.82 (1.87 to 32.6) 14.6 (1.35 to 157)
1st 0.323–2.688 0.78 (0.26 to 2.39) 11.6 (4.91 to 27.5) 12.5 (3.57 to 43.9) 6.29 (1.45 to 27.3) 24.9 (2.28 to 272)
p Value for trend 0.391 ,0.005 ,0.005 ,0.005 0.002
Serum gastrin quintiles (ng/l)
1st 2–20 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
2nd 25–30 1.25 (0.44 to 3.55) 1.99 (0.82 to 4.83) 1.56 (0.44 to 5.52) 8.19 (0.80 to 84.2) 1.75 (0.30 to 10.2)
3rd 35–55 1.58 (0.58 to 4.28) 2.45 (1.13 to 5.35) 1.82 (0.59 to 5.58) 10.6 (1.13 to 99.0) 1.66 (0.37 to 7.41)
4th 60–90 0.71 (0.19 to 2.66) 3.82 (1.77 to 8.23) 3.66 (1.23 to 10.9) 8.42 (0.97 to 73.2) 3.44 (0.82 to 14.5)
5th 95–462 1.63 (0.48 to 5.48) 8.99 (3.96 to 20.4) 12.8 (3.83 to 42.6) 21.8 (2.29 to 208) 3.68 (0.77 to 17.7)
p Value for trend 0.702 ,0.005 ,0.005 0.007 0.042
Values are represented as OR (95% CI).
*Including four histologically unclassifiable cases and 12 corresponding controls.
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regression with adjustment for the matching variables in the
original study design. Unconditional logistic regression pro-
duced estimates similar to comparable conditional regression
analyses. Tests of contrasts in ORs between subgroups of
subjects were performed by including an interaction term in the
statistical model. For tests of linear trend, the categorised
variable was treated as a continuous variable, and for tests of
homogeneity, the variable was represented with indicator
variables. Two-sided p values ,0.05 were considered signifi-
cant.
RESULTS
We studied 131 (76%) men and 42 (24%) women with 390 and
118 matched controls, respectively. In the non-cardia subsites,
there were 91 men and 38 women. In the cardia, predominance
for men was much more pronounced, with 40 men vs four
women. Serum was sampled between 1972 and 1986, with
98% of the samples collected between 1972 and 1977. Median
age at serum sampling was 45.6 (range 23.6–63.4) years
and median follow-up time to diagnosis of cancer was 11.9
(range 0.3–20.3) years in the cases. Median age at diagnosis
of cardia cancer was 57.5 (range 43.6–63.3) years, and
median age at diagnosis of non-cardia cancer was 55.8 (range
34.3–68.2) years. The time span over which the serum samples
were obtained preceded the introduction of proton pump
inhibitor medication in Norway.
As reported previously, the association between H pylori
seropositivity and cancer was highly dependent on the gastric
subsite14 (table 1). H pylori seropositivity was found in 90%
(116/129) of the non-cardia cases and in 43% (19/44) of
the cardia cases, as compared with 66% (247/376) and 71%
(93/132) in the respective control groups. There was a negative
association between the infection and cancer of the cardia (OR
0.27, 95% CI 0.12 to 0.59). This contrasted with the positive
association in the non-cardia subsites collectively (OR 4.75, 95%
CI 2.56 to 8.81; p,0.001). The OR in the antrum and pylorus
combined (OR 7.95, 95% CI 3.07 to 20.6) was non-significantly
higher (p = 0.09) than in the fundus and body combined (OR
2.67, 95% CI 1.14 to 6.25).
SERUM PGI:II
Figure 1 shows the individual PGI:II results. In non-cardia
subsites collectively, there was a strong association between
PGI:II and the subsequent development of cancer. The risk of
non-cardia cancer increased monotonously with decreasing
quintiles of PGI:II (table 1). A PGI:II ,2.69 (lowest quintile)
conferred an overall 11.6 (95% CI 4.91 to 27.5) times higher risk
of non-cardia cancer than a ratio .6.06 (highest quintile; p for
trend over quintiles ,0.001). The associations were similar for
the proximal and distal non-cardia subsites (data not shown).
With PGI:II values dichotomised, PGI:II ,2.5 was associated
with a 4.47 (95% CI 2.71 to 7.37) times higher risk of non-
cardia cancer than PGI:II .2.5 (table 2). A statistically
significant association between low PGI:II and non-cardia
cancer was found in both H pylori-positive and H pylori-negative
subjects when analysed separately (table 2).
In the cardia, quintiles of PGI:II showed no linear association
with risk of cancer (p for trend 0.391; table 1). However, when
PGI:II was dichotomised and H pylori-seropositive cases and
controls were analysed separately, an association between
atrophy and cardia cancer was found. H pylori-positive
individuals with a PGI:II ,2.5 had a 3.33 (CI 1.06 to 10.5)
times higher risk of developing cardia cancer relative to subjects
with PGI:II .2.5 (table 2). There were no H pylori-negative
cases or controls with PGI:II ,2.5 precluding an analogous
analysis of H pylori-negative subjects.
SERUM GASTRIN
Figure 2 shows the individual serum gastrin results. In non-cardia
subsites collectively, a monotonously increasing risk with increas-
ing serum gastrin quintiles was observed, the risk being 8.99 (95%
CI 3.96 to 20.4) times higher for gastrin values >95 ng/l than for
values (20 ng/l (table 1). The pattern was similar in proximal and
distal non-cardia subsites, with ORs tending to be slightly higher in
the distal subsites (data not shown). Length of time between the
last mealandserum sampling was known for 120 (93%) of thenon-
cardia cases and 352 (95%) of corresponding controls. In this
subgroup of subjects, the association between serum gastrin
concentration and cancer was estimated before and after adjust-
ment for time since the last meal. Overall, the adjustment did not
Figure 1 Serum pepsinogen I:II (PGI:II) in
patients with cancer and their controls by
subsite and Helicobacter pylori status.
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materially alter the point estimates for cardia or non-cardia
subsites. However, the adjustment increased the ORs in the distal
non-cardia subsites by approximately 30% within each of the
serum gastrin concentration quintiles. In an unconditional logistic
regression model with adjustment for the variables used for
matching in the study design, dichotomising serum gastrin values
at >60 ng/l was most discriminating, conferring a 3.18 (95% CI
2.03 to 4.99) times increased risk of non-cardia cancer relative to
gastrin concentrations ,60 ng/l. This association was apparent
and was of the same order of magnitude in both H pylori-positive
(OR 2.77, 95% CI 1.69 to 4.54) and H pylori-negative (OR 3.05, 95%
CI 0.71 to 13.1) individuals analysed separately (table 2).
In the cardia, there was no linear association between serum
gastrin concentration tertiles (p for trend 1.00), quartiles (p for
trend 0.41) or quintiles (p for trend 0.70; table 1) and later
development of cancer, nor did gastrin dichotomised at various
cut-off values show any association with cardia cancer. However,
separate analyses for H pylori-positive and H pylori-negative cases
and controls suggested associations proceeding in opposite
directions. In an unconditional logistic regression model,
hypergastrinaemia (cut-off at 60 ng/l) tended to be positively
associated with cardia cancer in H pylori-seropositive patients (OR
2.23, 95% CI 0.63 to 7.87) but negatively associated in H pylori-
seronegative patients (OR 0.38, 95% CI (0.05 to 3.03); a test for
homogeneity between ORs gave p = 0.093). Adjustment for time
since the last meal did not weaken the associations in the subset
of subjects for whom this information was available.
HISTOLOGICAL SUBTYPES
The cardia and non-cardia cancers had different distributions of
histological subtypes. Of the 129 non-cardia cancers, 59 (46%) were
intestinal, 35 (27%) diffuse and 31 (24%) mixed, and four (3%)
Table 2 Risk of adenocarcinoma for serum pepsinogen I:II ,2.5 (relative to serum pepsinogen I:II .2.5) and serum gastrin




Risk factor Overall Seropositive Seronegative
Non-cardia 129 cases, 376 controls 116 cases, 247 controls 13 cases, 129 controls
Pepsinogen I:II .2.5 1.00 (reference) 1.00 (reference) 1.00 (reference)
Pepsinogen I:II ,2.5 4.47 (2.71 to 7.37) 3.45 (2.01 to 5.91) 12.6 (2.25 to 70.7)*
p Value ,0.001 ,0.001 0.004
Gastrin ,60 ng/l 1.00 (reference) 1.00 (reference) 1.00 (reference)
Gastrin >60 ng/l 3.18 (2.03 to 4.99) 2.77 (1.69 to 4.54) 3.05 (0.71 to 13.1)
p Value ,0.001 ,0.001 0.133
Cardia 44 cases, 132 controls 19 cases, 93 controls 25 cases, 39 controls
Pepsinogen I:II .2.5 1.00 (reference) 1.00 (reference) 1.00 (reference)
Pepsinogen I:II ,2.5 1.60 (0.62 to 4.14) 3.33 (1.06 to 10.5) 
p Value 0.333 0.039
Gastrin ,60 ng/l 1.00 (reference) 1.00 (reference) 1.00 (reference)
Gastrin >60 ng/l 0.88 (0.37 to 2.06) 2.23 (0.63 to 7.87) 0.38 (0.05 to 3.03)
p Value 0.761 0.213 0.362
Risk of adenocarcinoma estimated by OR with associated 95% CI in an unconditional logistic regression model with adjustment for the matching variables in the original
study design.
*Unconditional logistic regression analysis without adjustment for the matching variables (only three cases with pepsinogen I:II ,2.5 precluded adjustment).
There were no H pylori seronegative cardia cases or controls with pepsinogen I:II ,2.5.
Figure 2 Serum gastrin in patients with
cancer and their controls by subsite and
Helicobacter pylori status.
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were of unclassifiable histological subtype. By contrast, the 44
cardia cancers comprised 31 (71%) intestinal, seven (16%) diffuse,
five (11%) mixed and one (2%) unclassifiable histological subtypes.
The proportion of intestinal to diffuse subtype was significantly
higher in the cardia versus non-cardia subsite (p,0.05).
In the non-cardia region, the risk of each of the three
histological subtypes increased similarly with decreasing quin-
tiles of PGI:II and increasing quintiles of serum gastrin (table 1).
In the cardia, however, the different adenocarcinoma
subtypes showed different associations with both PGI:II and
gastrin. For these analyses, the variables were dichotomised
because of the limited number of cardia cancers and controls.
And for comparison, analogous analyses based on dichotomised
variables were performed for the non-cardia subsites (table 3).
PGI:II ,2.5 (relative to PGI:II .2.5) was associated with an
increased risk of the diffuse subtype at both non-cardia (OR
3.21, 95% CI 1.27 to 8.13) and cardia subsites (OR 3.46, 0.32 to
37.5). Similarly, there was a tendency towards an association
between serum gastrin >60 ng/l (relative to serum gastrin
,60 ng/l) and the diffuse subtype in both the non-cardia (OR
2.11, 95% CI 0.92 to 4.86) and the cardia subsites (OR 5.30, 95%
CI 0.52 to 54.6). With respect to the intestinal subtype, both low
PGI:II and high serum gastrin showed disparate effects
between the two subsites. Low PGI:II was positively associated
with the intestinal subtype at non-cardia sites (OR 6.68, 95% CI
2.79 to 16.0), but apparently not at the cardia sites (OR 0.72,
95% CI 0.19 to 2.79; table 3). The contrast in ORs was highly
significant (p = 0.007). Likewise, hypergastrinaemia was posi-
tively associated with the intestinal subtype in non-cardia
subsites (OR 4.04, 95% CI 2.05 to 7.96), but not at the cardia
subsites (OR 0.59, 95% CI 0.22 to 1.58; table 3). This difference
in ORs was also highly significant (p = 0.002).
The eight cardia cancers that occurred in patients with
atrophic (PGI:II,2.5) stomachs were all H pylori positive (fig 2).
Three of these cancers were of intestinal, three were of diffuse
and two were of mixed histological subtype, and this distribu-
tion of histological subtypes was similar to that of the H pylori-
positive non-cardia cancers. The 36 cardia cancers that occurred
in patients with non-atrophic (PGI:II .2.5) stomachs were
predominantly H pylori negative (69%) and had a distribution of
histological subtypes that was different from the non-cardia
cancers, the intestinal subtype being more prevalent in the
cardia (78%) cancers than in the non-cardia (46%) cancers.
DISCUSSION
This study shows the association between the premorbid state of
the gastric mucosa and the location and histological subtypes of
gastric adenocarcinoma presenting over subsequent years.
Cancers of the mid and distal stomach of all histological subtypes
were positively associated with H pylori infection, atrophy and
hypochlorhydria. Cardia cancer was more complex; it was
negatively associated with H pylori infection and the predominant
intestinal subtype of cardia cancer was not associated with gastric
atrophy. However, in patients with H pylori infection, cardia
cancer was positively associated with atrophy and hypochlorhy-
dria. These findings can be explained by cardia cancer being of
two distinct aetiologies, some cases being similar to non-cardia
cancer and others having a different aetiology.
The findings with non-cardia cancer are consistent with
current knowledge that its development is a multistage
process.7 H pylori infection induces superficial gastritis, which
progresses to atrophic gastritis with loss of acid secretion and
then to dysplasia and cancer. Various bacterial, host and
environmental factors are known to contribute to the progress
through these different pre-cancerous stages.25
The multistage process of non-cardia cancer development has
been traditionally more strongly associated with the development
of the intestinal histological subtype of cancer, as the diffuse type
may develop in subjects with normal gastric mucosa.26 In the latter
cases, there is often a strong hereditary predisposition with
inherited germline mutations.27 Our current study, however, along
with that of Uemura et al,6 indicates that atrophy and hypochlorhy-
dria are associated with increased risk of the diffuse and mixed
histological subtypes, as well as with intestinal gastric cancer.
The association between atrophy and non-cardia cancer was
apparent in both the H pylori-seropositive and H pylori-seronega-
tive patients, the association being statistically non-significantly
stronger in the H pylori-seronegative subjects. H pylori seronega-
tivity in some of these individuals may be explained by atrophy
and hypochlorhydria causing loss of H pylori infection and
seropositivity.28–30 Previous studies have shown that patients with
evidence of atrophy and no evidence of H pylori have the highest
risk for cancer.30 Some of the non-cardia cancers may have arisen
from gastric atrophy due to causes other than H pylori—for
example, autoimmune atrophic gastritis.
In addition to using PGI:II as a marker of atrophy, we also used
serum gastrin as a marker of atrophy and hypochlorhydria.
Table 3 Risk of adenocarcinoma for serum pepsinogen I:II ,2.5 (relative to serum pepsinogen I:II .2.5) and serum gastrin




risk factor Overall* Intestinal Diffuse Mixed
Non-cardia 129 cases, 376 controls 59 cases, 173 controls 35 cases, 100 controls 31 cases, 91 controls
Pepsinogen I:II .2.5 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Pepsinogen I:II ,2.5 4.32 (2.58 to 7.24) 6.68 (2.79 to 16.0) 3.21 (1.27 to 8.13) 2.32 (0.86 to 6.25)
p Value ,0.001 ,0.001 0.014 0.097
Gastrin ,60 ng/l 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Gastrin >60 ng/l 2.97 (1.92 to 4.61) 4.04 (2.05 to 7.96) 2.11 (0.92 to 4.86) 2.40 (1.06 to 5.44)
p Value ,0.001 ,0.001 0.079 0.036
Cardia 44 cases, 132 controls 31 cases, 93 controls 7 cases, 21 controls 5 cases, 15 controls
Pepsinogen I:II .2.5 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Pepsinogen I:II ,2.5 1.56 (0.60 to 4.09) 0.72 (0.19 to 2.79) 3.46 (0.32 to 37.5) —
p Value 0.365 0.632 0.307
Gastrin ,60 ng/l 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Gastrin >60 ng/l 0.85 (0.38 to 1.88) 0.59 (0.22 to 1.58) 5.30 (0.52 to 54.6) 0.69 (0.06 to 8.04)
p Value 0.689 0.295 0.161 0.764
Risk of adenocarcinoma estimated by OR with associated 95% CI.
*Including four histologically unclassifiable cases and 12 corresponding controls.
– not applicable.
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Atrophic gastritis notably impairs the ability of the stomach to
secrete acid, which stimulates a rise in the circulating concentra-
tion of the hormone gastrin. Serum gastrin has been shown to be
an independent predictor of atrophic gastritis in subgroups with
and without H pylori infection.31 Similar to PGI:II, serum gastrin is
most sensitive to atrophic gastritis affecting the gastric body
where the acid-secreting parietal cells are located.32 Serum gastrin
increases linearly with an increase in grade of atrophy of the body
mucosa and exponentially with a decrease in peak acid output
from normal (.10 meq/h) to zero.33 In patients with achlorhydria
or severe hypochlorhydria (peak acid output ,1.1 meq/h), the
degree of accompanying hypergastrinaemia decreases linearly
with increasing grade of antral atrophy.33 This moderating
influence of antral atrophy is thought to be due to loss of antral
G cells, and thus inability to produce the high rate of gastrin
secretion stimulated by profound hypochlorhydria.33
There was a particularly strong association between in-
crease in serum gastrin level and subsequent risk of non-cardia
cancer. It is possible that the rise in serum gastrin level associated
with atrophy and low acidity may promote the carcinogenic
process.34 The hypergastrinaemic mouse model develops invasive
gastric cancer, an effect that is markedly accelerated by H pylori
infection and inhibited by gastrin receptor antagonism.35–37
The state and function of the gastric mucosa associated with
cardia cancer is more complex than that associated with non-cardia
cancer. In contrast with non-cardia cancer, there was a negative
association between H pylori infection and cardia cancer. As H pylori
infection causes atrophy and hypochlorhydria, we expected to find
a lower prevalence of atrophy and hypochlorhydria in patients with
cardia cancers than in controls because of the lower prevalence of H
pylori in patients with cardia cancer (table 1). Such a finding would
be consistent with H pylori protecting from cardia cancer by the
same mechanism by which it predisposes to non-cardia cancer—
that is, by reducing gastric acidity. However, despite the
significantly lower prevalence of H pylori infection in patients with
cardia cancer (43% vs 71% in controls), the prevalence of atrophy
was at least as high in the cases (18%) as in the controls (13%). The
reason for this unexpected finding was that the prevalence of
atrophy in the H pylori-positive patients with cardia cancer was
significantly higher than the H pylori-positive controls. Patients
with cardia cancer were thus characterised by having a significantly
lower prevalence of H pylori infection but higher prevalence of
atrophy in those with the infection than in the controls.
What is the explanation for the complex association between
the premorbid state of the gastric mucosa and cardia cancer?
The lower prevalence of H pylori infection is consistent with H
pylori having some protective effect. However, the high
prevalence of atrophic gastritis in the H pylori-infected subjects
suggests that atrophic gastritis due to H pylori predisposes to
cardia cancer. The most plausible explanation for our findings
is that cancer of the cardia region has a heterogeneous aetiology
and arises by two different pathways, with H pylori exerting an
opposite influence on the two pathways.
The positive association with atrophic gastritis in the H pylori-
infected patients with cardia cancer is consistent with a subgroup
of cardia cancers having an aetiology similar to non-cardia
cancer—that is, due to H pylori infection progressing to atrophic
gastritis and cancer. The serological markers of atrophy detect
atrophy mostly involving the body mucosa.32 38 39 Body atrophy
induced by H pylori gastritis causes distal regression of the
apparent cardia–oxyntic junction because of loss of specialised
cells.13 Our finding is consistent with a proportion of the cardia
cancers having arisen from this process and thus being of an
aetiology similar to non-cardia cancer. Ye et al40 recently reported
that cardia cancer was not associated with H pylori infection but
with gastric atrophy, and their observation is also thus consistent
with atrophy being involved in a subgroup of cardia cancers.
The lower prevalence of H pylori infection in patients with
cardia cancer supports an additional aetiological pathway in
which H pylori may exert a protective influence. Several studies
have reported a negative association between H pylori infection
and oesophageal adenocarcinoma.40 41 A subgroup of the cardia
cancers may have an aetiology similar to oesophageal adeno-
carcinoma and be subject to a H pylori protective influence.
Proximal expansion of the cardia mucosa can arise by
metaplasia of oesophageal mucosa, which is the same process
that is thought to lead to oesophageal adenocarcinoma and to
be induced by reflux of gastric acid.9–12 The mechanism by
which H pylori infection may protect from this process is
unclear, but it may be because it causes a fall in acid output
with advancing years owing to the development of atrophy.42 43
The analyses of the histological subtypes provide further
evidence of two distinct aetiologies of cardia cancer. Atrophy
tended to increase the risk of the diffuse subtype of cardia cancer to
an extent similar to which it increased the diffuse subtype of non-
cardia cancer. This was apparent by using either PGI:II or gastrin as
the marker of atrophy. However, our data suggested that atrophy
does not increase the risk of intestinal-type cardia cancer, which
was in contrast with the increased risk of intestinal-type cancer in
the non-cardia region. The contrast in associations between
atrophy and intestinal-type cancer in the cardia versus non-cardia
regions was highly significant when using either low PGI:II
(p = 0.007) or high gastrin (p = 0.002) as risk indicators. The
diffuse-type cancers at the cardia thus seems to be aetiologically
similar to diffuse non-cardia cancers, whereas the intestinal-type
cancers at the cardia (or at least most of them) are aetiologically
distinct from intestinal-type cancers in the non-cardia region.
The cardia cancers that occurred in patients with atrophic
gastritis (all of whom were H pylori positive) had similar
proportions of intestinal and diffuse histological subtypes as in
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the non-cardia cancers. This is consistent with them being of an
aetiology similar to non-cardia cancer arising from H pylori-
induced atrophic gastritis (fig 2). However, the cardia cancers
occurring in patients with non-atrophic stomachs (69% of
which were H pylori seronegative) had a much higher
proportion of intestinal versus diffuse histological subtype
(7:1). This predominant intestinal histological subtype is
similar to that reported in oesophageal adenocarcinoma44 and
is consistent with this subgroup being of an aetiology similar to
oesophageal adenocarcinoma.
Our observations are relevant to the hypothesis that H pylori
infection may protect from oesophageal adenocarcinoma as
well as predispose to gastric cancer and that both effects are
mediated by gastric atrophy. To demonstrate a possible
protective effect of H pylori infection on oesophageal adeno-
carcinoma via gastric atrophy, it will be essential to study only
oesophageal adenocarcinomas well clear of the gastro-oeso-
phageal junction. Inclusion of any cardia cancers will obscure a
possible protective effect of atrophy due to the subgroup of
cardia cancers associated with gastric atrophy.
Our finding may also be relevant to the conflicting reports on
the association between H pylori infection and cardia cancer.1 45 In
general, the association has tended to be negative in studies
originating from the West and positive in studies from the
East.1 45 Our observation of some cardia cancers aetiologically
resembling oesophageal adenocarcinoma and others resembling
non-cardia adenocarcinoma may explain the conflicting associa-
tions of cardia cancer with H pylori. In parts of the world where
oesophageal adenocarcinoma is relatively common, most cardia
cancers are aetiologically similar to oesophageal adenocarcinoma
and a protective effect of H pylori infection and associated atrophy
is apparent. By contrast, in parts of the world such as the East
where oesophageal adenocarcinoma is rare and non-cardia
gastric cancer is common, the predominant aetiological type of
cardia cancer will resemble non-cardia cancer and show a positive
association with H pylori and atrophic gastritis.
One practical implication of our findings is that the state of the
gastric mucosa may provide a key to determining the origin of
cardia cancer. As already discussed, it is usually impossible to
determine the origin of such cancers by examining them grossly
or microscopically. However, if examination of the stomach well
clear of the cancerous process reveals atrophic gastritis, then
cardia cancer of the intestinal histological subtype is likely to be
aetiologically similar to non-cardia cancer and to have arisen
from original gastric mucosa. By contrast, if the patient has a
healthy non-atrophic gastric mucosa, then cardia cancer of the
intestinal histological subtype is likely to be of an aetiology
similar to oesophageal adenocarcinoma and to have arisen from
metaplastic oesophageal mucosa produced by gastroesophageal
reflux. We have recently proposed that cardia cancers of the
intestinal histological subtype arising in patients with evidence of
gastric atrophy should be termed type A and those arising in
patients without gastric atrophy termed type B.46 Cardia cancers
of the diffuse histological subtype are likely to be gastric in origin.
In conclusion, our studies indicate that cardia cancers
probably comprise two distinct aetiological subtypes, one
resembling non-cardia gastric cancer and positively associated
with H pylori atrophic gastritis and the other resembling
oesophageal adenocarcinoma and negatively associated with
H pylori atrophic gastritis. Further studies with larger numbers
of cancers are required to determine whether the state of the
gastric mucosa will indeed provide the key to differentiate
between gastric versus oesophageal origin of cardia cancers.
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Single aetiology and dual
associations of cardiac cancer
With interest we read the article by Hansen et al.
(Gut 2007;56:918–25). The authors have to
be congratulated on their contribution which
profoundly adds to our understanding of the
pathophysiology leading to oesophageal and
gastric cancer. In addition, the paper points out
the difficulties we have to correctly assign
tumours of the oesophago-gastric junction
(oesophageal vs gastric?). Cardiac cancers were
subtyped for their associations with serum
anti-Helicobacter pylori IgG antibody titer and
biochemical markers of loss of gastric secretory
function associated with atrophy (pepsinogen I/
II ratio and serum gastrin concentration).
However, the anatomic criterium to define
cardiac carcinoma, that is, tumours centred
within 2 cm distal to the oesophago-gastric
junction, is inaccurate. Interpretation of the data
should be conducted with the inclusion of
clear, anatomical and histopathological cri-
teria.
It is well accepted that cardiac cancer and
adenocarcinoma of the oesophagus share
epidemiological and pathogenetic features.1 2
After birth the oesophagus is lined by squa-
mous epithelium, whereas the stomach is lined
by gastric oxyntic mucosa (with parietal and
chief cells).1 3 Due to gastro-oesophageal
reflux, squamous epithelium is damaged and
replaced by cardiac mucosa (CM). Thus CM is
interposed between squamous and oxyntic
mucosa. Via intestinal metaplasia and dyspla-
sia CM may progress towards adenocarcinoma
of the oesophagus.1–3 Anatomy proves that CM
is oesophageal: unlike the stomach, the oeso-
phagus has submucosal glands. Histopathology
studies of full-thickness oesophago-gastric
specimens revealed that CM is only present
above submucosal glands, whereas gastric
oxyntic mucosa is not underlined by submu-
cosal glands.1 CM is columnar-lined oesopha-
gus and not stomach.1 Using multilevel biopsy
sampling around the endoscopic visible oeso-
phago-gastric junction in patients with gastro-
oesophageal reflux disease, Ringhofer et al.4
showed that CM cannot be differentiated from
gastric oxyntic mucosa by endoscopy. Reflux-
damaged columnar-lined oesophagus was mis-
taken as proximal stomach in 51% of the
patients.4 Based on histopathology, tumours
arising within CM are of oesophageal origin,
while those arising within oxyntic mucosa are
of gastric origin.1 3
What the authors believe to be a ‘‘dual’’
aetiology are in fact ‘‘dual associations’’. Their
data prove that oesophageal adenocarcinoma
arising within CM may be present with or
without gastric atrophy and H pylori infection
of the stomach.1 H pylori may also infect
columnar-lined oesophagus (ie, CM)1 3 and be
protective against adenocarcinoma, possibly
due to atrophy-induced changes in the compo-
sition of the refluate.1
Taken together, the aetiology of cancers at
the oesophago-gastric junction can only be
defined by histopathological criteria: tumours
arising within cardiac and oxyntic mucosa are
of oesophageal and gastric origin, respec-
tively.1 3 Consequently, cardiac carcinomas
have to be treated as oesophageal cancers and
tumours arising from oxyntic mucosa as gastric
malignancies. Cardiac cancer has a single
aetiology, gastro-oesophageal reflux, but may
have associations with H pylori infection and
gastric atrophy. The authors are kindly asked
to address this issue.
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Authors’ reply
We are grateful to Dr Lenglinger and colleagues
for their interest in our paper and thoughtful
comments. However, we disagree with their
contention that cardia cancer has a single
aetiology and is always a consequence of
gastro-oesophageal reflux.
We agree that cardia cancer shares epide-
miological similarities with oesophageal ade-
nocarcinoma but would also point out that
there are clear epidemiological differences
between these two cancers.1 2 Indeed, the
epidemiology of cardia cancer tends to share
epidemiological features with both oesopha-
geal adenocarcinoma and non-cardia gastric
cancer consistent with these cancers being a
mixture of two aetiological subtypes – one
being similar to non-cardia cancer and one
being similar to oesophageal adenocarcinoma.
We disagree that cardia mucosa always
represents a metaplastic response. Indeed,
cardia mucosa at, or proximal to, the angle of
His has been shown to be established during
gestation and present at birth.3 Whether this
transition zone between the squamous epithe-
lium of the oesophagus and the oxyntic
mucosa of the stomach is oesophageal or
gastric may in the end be a matter of
definition.
We also disagree that the only aetiology of
carditis and columnar intestinal metaplasia at
the gastro-oesophageal junction is gastro-oeso-
phageal reflux. Helicobacter pylori-induced
atrophic gastritis may also produce inflamma-
tion, loss of oxyntic glands and intestinal
metaplasia at the gastric cardia.4–6 Whereas
reflux disease causes intestinal metaplasia
extending proximally to the original squamo-
columnar junction, H pylori atrophic gastritis
causes intestinal metaplasia extending distally
from the original squamocolumnar junction.7 8
In practice, it is very difficult to determine by
purely examining the columnar mucosa at the
gastro-oesophageal junction whether it has
developed from original oesophageal or origi-
nal gastric mucosa. Contrary to Dr Lenglinger
and colleagues’ statement that all cardia
tumours are oesophageal in origin, the latest
version of the International Classification of
Diseases classifies cardia tumours as gastric
tumours (C 16.0).9
We agree that in the Western world where H
pylori and gastric atrophy are relatively rare, the
majority of cancers at the gastro-oesophageal
junction will have arisen as a consequence of
gastro-oesophageal reflux. However, in China
and Japan, such cancers are mainly of the
other aetiological subtype being a consequence
of H pylori-induced atrophic gastritis.10 11
Consequently, at a global level, we believe that
cancer of the gastro-oesophageal junction and
cardia can be of two aetiological subtypes. As
proposed in our paper, examination of the
gastric mucosa distant from the gastro-oeso-
phageal junction is likely to be helpful in
determining the particular aetiology of gastro-
oesophageal junction cancer in individual
patients.
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